Chardan Capital Reaffirms Neutral Rating for Outlook Therapeutics (NASDAQ:OTLK)

Chardan Capital reissued their neutral rating on shares of Outlook Therapeutics (NASDAQ:OTLK - Free Report) in a research note released on Tuesday,Benzinga reports. Chardan Capital currently has a $3.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Guggenheim restated a "buy" rating and set a $12.00 target price on shares of Outlook Therapeutics in a research report on Friday, January 17th. BTIG Research decreased their target price on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating for the company in a research report on Friday, November 29th. Finally, HC Wainwright decreased their target price on Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.

Outlook Therapeutics Trading Down 4.9 %

Outlook Therapeutics stock traded down $0.08 during mid-day trading on Tuesday, hitting $1.56. The stock had a trading volume of 753,835 shares, compared to its average volume of 613,068. The stock has a 50-day simple moving average of $1.89 and a two-hundred day simple moving average of $4.33. The stock has a market capitalization of $49.95 million, a PE ratio of -0.21 and a beta of 0.58. Outlook Therapeutics has a 12 month low of $0.87 and a 12 month high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings results on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04). Sell-side analysts expect that Outlook Therapeutics will post -2.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Outlook Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its position in shares of Outlook Therapeutics by 55.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company's stock valued at $275,000 after purchasing an additional 18,287 shares during the period. State Street Corp grew its position in shares of Outlook Therapeutics by 10.0% in the 3rd quarter. State Street Corp now owns 232,542 shares of the company's stock valued at $1,242,000 after purchasing an additional 21,201 shares during the period. Geode Capital Management LLC grew its position in shares of Outlook Therapeutics by 49.2% in the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company's stock valued at $1,826,000 after purchasing an additional 112,812 shares during the period. Barclays PLC boosted its position in Outlook Therapeutics by 677.4% during the 3rd quarter. Barclays PLC now owns 20,943 shares of the company's stock worth $111,000 after acquiring an additional 18,249 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Outlook Therapeutics during the 3rd quarter worth approximately $199,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.